Marketing: Page 48
-
Kite first to file for CAR-T approval in Europe
In the U.S., however, Novartis looks set to secure the first approval for a CAR-T therapy, winning the unanimous support of a FDA advisory panel in July.
By Suzanne Elvidge • Aug. 2, 2017 -
Idhifa approval furthers Celgene's diversification goals
Revlimid continues to make up 60% of Celgene's revenues, but a new product for acute myeloid leukemia could help spread the wealth.
By Jacob Bell • Aug. 1, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Puma's early Nerlynx launch raises doubts of a takeover
The company's decision to commercialize its breast cancer drug dampens the prospect of a near-term acquisition, according to a recent analyst report.
By Jacob Bell • Aug. 1, 2017 -
Sponsored by MicroMass Communications, Inc.
Instead of being patient centered, try being patient informed
To be successful, a brand must go beyond persuasive product messages and work to support the whole patient, not just their clinical needs.
By Meredith Terry, Senior Behaviorist • Aug. 1, 2017 -
Vertex wins new Kalydeco approval, ups sales forecast
A label expansion will increase the patient population treatable by Vertex's older cystic fibrosis drug, strengthening the biotech's position.
By Ned Pagliarulo • Aug. 1, 2017 -
Express Scripts shuts out 64 branded drugs from 2018 formulary
Among the drugs excluded from the PBM's preferred list were Amgen's Neupogen, Eli Lilly's Forteo and Synergy Pharmaceuticals' newly approved Trulance.
By Ned Pagliarulo • July 31, 2017 -
AbbVie confident in strategy as Humira mints money
Despite growing competitive threats in immunology, AbbVie believes it can maintain its leadership position.
By Ned Pagliarulo • July 28, 2017 -
Tesaro lands licensing, supply agreements for Zejula
Two separate deals have Takeda handing over $100 million upfront for rights to the cancer med and STA Pharmaceutical providing the materials to make it.
By Jacob Bell • July 27, 2017 -
FDA
GSK gets go-ahead for new Benlysta formulation
Approval brings the first self-injectable treatment for the most common form of lupus to market, according to the British drugmaker.
By Jacob Bell • July 26, 2017 -
Merck undercuts Pfizer on Remicade biosimilar price
Looking to steal share, Merck priced its biosimilar version at a 35% discount to Remicade's list price, upping the threat faced by J&J's blockbuster biologic.
By Ned Pagliarulo • July 26, 2017 -
AbbVie faces $150M in damages in AndroGel trial
The Illinois drugmaker will have to pay up for fraudulent representation of the testosterone treatment and faces further damages as class action suits progress.
By Suzanne Elvidge • July 26, 2017 -
Celgene pays $280M to make fraud allegations go away
The big biotech admitted no wrongdoing, but settled the lawsuit in hopes of putting the off-label promotion matter in the past and off its balance sheet.
By Jacob Bell • July 26, 2017 -
Spinraza launch set for blockbuster trajectory
Biogen surprised the markets with stronger-than-expected earnings for its rare disease drug. But can those sales last?
By Lisa LaMotta • July 25, 2017 -
5 orphan drugs receive EMA thumbs-up
Pfizer and Merck KGaA's Bavencio and Novartis' Rydapt were among the 11 drugs recommended for approval during the Committee for Medicinal Products for Human Use's July meeting.
By Jacob Bell • July 21, 2017 -
FDA
May day: Amgen, Novartis lock down lead for CGRP
The FDA gave a May 17 target action date for erenumab, a calcitonin gene-related peptide that the drugmakers plan to market under the name Aimovig.
By Jacob Bell • July 21, 2017 -
Takeda shuffles sales force as restructuring continues
The Japanese pharma has axed and relocated hundreds of sales positions as it continues to rejigger its portfolio.
By Suzanne Elvidge • July 19, 2017 -
PhRMA finally talks drug pricing in new campaign
The trade group's newest campaign aims to tackle frequently asked drug cost questions, while also defending pharma's role in pricing decisions.
By Jacob Bell • July 19, 2017 -
Sponsored by ZS Associates
Patient centricity's challenges and opportunities
Can pharma companies truly be patient-centric when they’re so far from the patient?
July 18, 2017 -
J&J: Remicade holding up better than expected
While second quarter sales slipped 14% for the anti-inflammatory drug, the big pharma noted that biosimilars played a muted role in that decline.
By Jacob Bell • July 18, 2017 -
J&J's Tremfya approved, further crowding IL-inhibitor market
Tremfya, approved to treat plaque psoriasis, will directly compete with Novartis' Cosentyx and Eli Lilly's Taltz.
By Jacob Bell • July 14, 2017 -
Sunovion sheds asthma brands to focus on COPD
The Massachusetts drugmaker recently acquired rights to three COPD treatments from Novartis and hopes to soon win approval for its own developed therapy.
By Suzanne Elvidge • July 14, 2017 -
Parkinson's drug Xadago launches in US
US WorldMeds, which holds stateside commercialization rights to the drug, plans to have more than 60 sales reps support the launch.
By Jacob Bell • July 12, 2017 -
Lisa LaMotta/BioPharma Dive
Allergan conflicted about teenage Botox market in light of growing demand
Allergan CEO Brent Saunders spoke out against the use of medical aesthetic products for teenagers in a blog post this week, calling for stakeholders to start a conversation about the use of products in this age group.
By Lisa LaMotta • July 12, 2017 -
Allergan has its eye on social media with #EyePic campaign
Dublin, Ireland-based pharma Allergan strives to boost sales through its latest awareness push.
By Suzanne Elvidge • July 12, 2017 -
Novartis hits pause on Fovista agreement
The Swiss drugmaker is no longer obligated to develop and commercialize Ophthotech's drug, at least until data from the OPH1004 study becomes available.
By Jacob Bell • July 10, 2017
Previous
